Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in mono...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Riccardo G. Borroni, Piergiorgio Malagoli, Luigi Gargiulo, Mario Valenti, Giulia Pavia, Paola Facheris, Emanuela Morenghi, Isotta Giunipero di Corteranzo, Alessandra Narcisi, Michela Ortoncelli, Paolo Dapavo, Antonio Costanzo
Formato: article
Lenguaje:EN
Publicado: Society for Publication of Acta Dermato-Venereologica 2021
Materias:
risankizumab
psoriasis
real-life
Dermatology
RL1-803
Acceso en línea:https://doaj.org/article/20c28872390140f28af22f527d4296d6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares